Summary of safety of anticoagulant use in pregnancy and during breastfeeding
| Anticoagulant . | Safe duringpregnancy . | Safe duringbreastfeeding . | Evidence-based summary . |
|---|---|---|---|
| Heparins | Yes | Yes | Does not cross the placenta; extensive safety data from observational studies |
| VKAs | No | Yes | Crosses the placenta; may cause coumadin embryopathy (if used between 6th and 12th week), fetal bleeding, and neurodevelopmental deficits |
| DOACs | No | No | Crosses the placenta; reproductive effects unknown |
| Danaparoid | Yes | Yes | Does not cross the placenta |
| Fondaparinux | Probably yes | Yes | Crosses the placenta to some extent; limited data suggest it is safe for the fetus |
| Anticoagulant . | Safe duringpregnancy . | Safe duringbreastfeeding . | Evidence-based summary . |
|---|---|---|---|
| Heparins | Yes | Yes | Does not cross the placenta; extensive safety data from observational studies |
| VKAs | No | Yes | Crosses the placenta; may cause coumadin embryopathy (if used between 6th and 12th week), fetal bleeding, and neurodevelopmental deficits |
| DOACs | No | No | Crosses the placenta; reproductive effects unknown |
| Danaparoid | Yes | Yes | Does not cross the placenta |
| Fondaparinux | Probably yes | Yes | Crosses the placenta to some extent; limited data suggest it is safe for the fetus |
Data adapted.15
DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.